ReShape Medical Announces Initiation of U.S. Clinical Study for Weight Loss; First Patient Receives ReShape Dual Balloon Device for Non-Surgical Weight Loss

SAN CLEMENTE, Calif., March 3 /PRNewswire/ -- ReShape Medical(TM), Inc. announced today that it has initiated a U.S. Investigational Device Exemption (IDE) clinical study to assess the safety and effectiveness of its non-surgical, dual-balloon device for weight loss. The ReShape Balloons are designed to be a treatment for the millions who want support with weight loss, without the invasiveness of surgery. The ReShape device occupies existing space in the stomach to reduce its capacity for food. The balloons remain in place for six-months and are then removed.

Dr. Quebbemann added, “Countless Americans have grown beyond a healthy weight and struggle with conventional methods of weight loss, but can’t or won’t undergo surgery. This group is ideally suited for a non-surgical weight loss treatment such as the ReShape device being evaluated in this study.”

About ReShape Medical, Inc.

CAUTION--Investigational device. Limited by United States law to investigational use.

CONTACT: ReShape Medical, Inc., +1-949-429-5001, info@reshapemedical.com

Web site: http://www.reshapemedical.com/

MORE ON THIS TOPIC